Medical high-frequency hyperthermia device ‘REMISSION 1℃’/Source = AdipoLABs

The medical high-frequency device 'REMISSION 1°C' introduced at the International Virus Research Alliance (IVRA), which was held online and offline of COEX, on September 29th of last year as a joint cooperative body for the treatment of COVID-19, is capturing the attention by presenting a new medical paradigm with the possibility of 'immune treatment' as the third year of the COVID-19 pandemic approaches.

◆Medical high-frequency device ‘REMISSION 1℃’ approved for pain relief, immunity boosting, and even cancer treatment

REMISSION 1℃ cures us based on a principle that increased deep heat by raising our body temperature above 40℃ through high frequency waves will result in a necrosis of heat-vulnerable cancer cells while promoting blood circulation and improving immunity. Based on this, the device has been certified for use by the Ministry of Food and Drug Safety in 2015 as a medical device that can treat cancer and relieve pain.

Our body contains many autoimmune cells. Among them, the most important immune cells are NK (Natural Killer Cell) cells. NK cells, also known as natural killer cells, are important cells responsible for innate immunity and they are representative autoimmune cells that protect the human body by attacking virus-infected cells or tumor cells.

When body temperature rises, many changes occur in the human body. As body temperature rises, blood flow increases and the body's immunity also increases. As immunity increases, viruses that have infiltrated the human body can be killed and secondary infections caused by viruses can be reduced or prevented.

7th Asian Hyperthermia Oncology Society Academic Seminar / Source = AdipoLABs

◆Patients infected with COVID-19 can be treated with hyperthermia therapy

The COVID-19 virus penetrates our bodies and infects human cells in organs, causing secondary and tertiary diseases, leading to serious sequelae or death. It is important to increase autoimmunity in the early stages of COVID-19 infection to kill the virus or prevent it from spreading and worsening within the human body due to infection.

 
Accordingly, it is known that it is a common method to artificially increase the number of neutralizing antibodies through a vaccine to increase immunity, but overcoming the harmful COVID-19 virus to the human body by increasing autoimmunity is a prerequisite for treatment. ‘REMISSION 1℃’ is a safe and effective method to boost the body’s autoimmunity.

In fact, at last year's IVRA conference, the results of treating COVID-19 patients using AdipoLABs' high-frequency hyperthermia cancer treatment device ' REMISSION 1℃' conducted by Professor Jang Hong-seok's team at Seoul St. Mary's Hospital and Seosan Medical Center were announced, drawing abundant attention.

According to published research results, an average of 4 treatments were administered to 20 domestic COVID-19 patients starting May 13th last year, and the effect of treatment was confirmed to be negative in all patients.

For example, as a result of measuring CT values ​​before and after treatment for 20 domestic patients, the average value of the E gene increased from 23.66 before treatment to 32.63 after treatment. In addition, the average value of the RdRP S gene increased from 24.07 to 33.18 after treatment, and the average value of the N gene increased from 24.07 to 33.18 after treatment. Therefore statistically significant results were obtained with the average value before treatment increasing from 25.22 to 33.24 after treatment.

 
For reference, the CT value of about 35 to 40 is the standard for distinguishing between positive and negative. If it is lower than this value, it is judged positive, and if it is higher, it is judged negative. Between CT values that are same positive, the one with a lower CT value indicates a faster virus being replicated with a higher transmissibility.

Regarding this, IVRA Vice Chairman Kim Seon-man said, “There is a disadvantage in that there are few sample cases for patient treatment, but considering that the negative standard is set at a CT value of 29.5 or higher, the result of treating a COVID-19 patient using ‘REMISSION 1℃’ and acquiring CT value of 32 or higher is very meaningful,” he said. “If ‘REMISSION 1℃’ is applied globally, we can eliminate the contagiousness of mild and asymptomatic patients with COVID-19 and return to daily life early.”

Han Sung-ho, CEO of AdipoLABs, who served as the co-leader of the IVRA event, said, “Despite the domestic and foreign economic difficulties due to the COVID-19 pandemic, REMISSION 1℃ has improved the health of many patients.” He added, “Hyperthermia therapy increases immunity to fight the COVID-19 virus. We have achieved monumental results in treatment and hope that by donating 21 units of our REMISSION 1°C, to member countries, we will be able to prove the effectiveness of immunotherapy for many patients infected with the COVID-19 virus.”

링크 : https://www.getnews.co.kr/news/articleView.html?idxno=573281